Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001209191-23-021286
Filing Date
2023-03-27
Accepted
2023-03-27 17:49:36
Documents
1
Period of Report
2023-03-24

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 3851
  Complete submission text file 0001209191-23-021286.txt   5207
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Issuer) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 1600 WEST END AVENUE SUITE 1300 NASHVILLE TN 37203
Business Address
Bitterman Chris T. (Reporting) CIK: 0001969681 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-33637 | Film No.: 23765677